Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EAU 2026 | Intravesical erdafitinib in BCG-unresponsive NMIBC: local efficacy, minimal systemic exposure

Antoni Vilaseca • 15 Mar 2026

EAU 2026

Antoni Vilaseca, MD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses the potential of intravesical erdafitinib for treating high-risk non-muscle-invasive bladder cancer, highlighting its localized exposure and reduced systemic side effects. Dr Vilaseca notes that erda-iDRS Phase I trial focused on patients with papillary tumors relapsing after BCG, excluding those with carcinoma in situ (CIS), and suggests that the high concentration of erdafitinib in urine with minimal systemic absorption could offer significant benefits. This interview took place at the 41st Annual EAU Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.